The p53 gene in soft tissue sarcomas: Prognostic value of DNA sequencing versus immunohistochemistry

Anticancer Research

Volumn 18, Issue 1 A, 1998, Pages 183-187

  Taubert, H ^a   Wurl P ^a   Bache, M ^a   Meye, A ^a   Berger, D ^a   Holzhausen, H J ^a   Hinze, R ^a   Schmidt, H ^a   Rath, F W ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Immunohistochemistry; Mutation; p53; STS

Indexed keywords

ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DO 1; MONOCLONAL ANTIBODY DO 7; MONOCLONAL ANTIBODY PAB 1801; MONOCLONAL ANTIBODY PAB 240; POLYCLONAL ANTIBODY; POLYCLONAL ANTIBODY CM 1; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DNA CONFORMATION; DNA SEQUENCE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SARCOMA; SINGLE STRAND CONFORMATION POLYMORPHISM; SOFT TISSUE SARCOMA;

DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; NEOPLASMS, NERVE TISSUE; PROGNOSIS; SARCOMA;

EID: 0031921505     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Rogel A, Popliker M, Webb CG, and Oren M: p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol 5: 2851-2855, 1983.
2. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, and Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms a hsc 70-p53 complex with an altered half-life. Mol Cell Biol 8: 531-539, 1988.
3. Van den Berg FM, Tigges A, Schipper M, Den Hartog-Jager C, Kroes W, and Walboomers J: Expression of the nuclear oncogene p53 in colon tumors. J Pathol 157: 193-199, 1988.
4. Bartek J, Iggo R, Gannon J, and Lane DP: Genetic and immunohistochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5: 893-899, 1990.
5. Hollstein M. Sidransky D, Vogelstein B, and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
6. Marks JR, Davidoff AM, Kerns BJ, Humphrey, PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC, Berchuck A: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51: 2979-2784, 1991.
7. Harris CC and Hollstein M: Clinical implications of the p53 tumor-suppressor gene. New Engl J Med 329: 1318-1327, 1993.
8. Baas IO, Mulder JWR, Offerhaus JA, Vogelstein B, and Hamilton SR: An evaluation of mutant p53 gene products in archival colorectal neoplasms. J Pathol 172: 5-12, 1994.
9. Greenblatt MS, Bennett WP, Hollstein M, and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
10. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon R J, Thomas G: Association of p53 mutations with short survival in colorectal cancer. Gasteroenterology 106: 42-48, 1994.
11. Bergh J, Norberg T, Sjögren S, Lindgren A, and Holmberg L: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1: 1029-1034, 1995.
12. Goh HS, Yao J, and Smith DR: p53 point mutation and survival in colorectal cancer patients. Cancer Res 55: 5217-5221, 1995.
13. Lim BHG, Soong R, Grieu F, Robbins PD, House AK, and Iacopetta BJ: p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int J Cancer 69: 200-204, 1996.
14. Hernandez L, Fest T, Cazarola M, Teruya-Feldstein J, Bosch F, Peinado MA, Piris M A, Montserrat E, Cardesa A, Jaffe ES, Campo E, Raffeld M: p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87: 3351-3359, 1996.
15. Iggo R, Gatter K, Lane DP, and Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675, 1990.
16. Davidoff AM, Humphrey PA, Iglehart JD, and Marks JR: Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 88: 5006-5010, 1991.
17. Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF, and Linnolila RI: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 mutations. Oncogene 7: 743-749, 1992.
18. Esrig, D, Spruck CH, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA, and Cote RJ: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143: 1389-1397, 1993.
19. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang Z-F, Rosai J, Reuter VE, and Pellicer A: p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 56: 347-353, 1994b.
20. Costa A, Marasca R, Valentins B, Savarino M, Faranda A, Silvestrini R, and Torelli G: p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancer. J Pathol 176: 45-53, 1995.
21. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, and Lane DP: p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87: 7555-7559, 1990.
22. Wynford-Thomas D: p53 in tumour pathology: can we trust immunocytochemistry? J Pathol 166: 329-330, 1992.
23. Hall PA and Lane DP: p53 in tumour pathology: can we trust immunohistochemistry?-revised! J Pathol 172: 1-4, 1994.
24. Ozbun M and Butel JS: Tumorsuppressor p53 mutations and breast cancer: a critical analysis. Adv Cancer Res 66: 71-141, 1995.
25. Gottlieb MG, and Oren M: p53 in growth control and neoplasie. Bioch et Biophys Acta 1287: 77-102, 1996.
26. Bristow RG, Benchimol S, and Hill RP: The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol 40: 197-223, 1996.
27. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, and Woodruff JM: Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54: 794-799, 1994.
28. Kawai A, Noguchi M, Beppu Y, Yokoyama R, Mukai K, Hirohashi S, Inoue H, and Fukuma H: Nuclear immunoreactions of p53 protein in soft tissue sarcomas. Cancer 73: 2499-2505, 1994.
29. Taubert H, Meye A, and Würl P: Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res 56: 4134-4136, 1996.
30. Würl P, Taubert H, Meye A, Berger D, Lautenschläger C, Holzhausen H-J, Schmidt H, Kalthoff H, Dralle H, and Rath F-W: Prognostic value of immunohistochemistry for p53 in primary soft tissue sarcomas: a multivariate analysis of five antibodies. J Clin One Cancer Res 123: 502-508, 1997.
31. Taubert H, Würl P, Meye A, Berger D, Thamm B, Neumann K, Hinze R, Schmidt H, and Rath F-W: Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma. Cancer 76: 1187-1196, 1995.
32. Vojtesek B, Bartek J, Midgley CA, and Lane DP: An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151: 237-244, 1992.
33. Stephen CW, Helminen P, and Lane, DP: Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insight into antibody-peptide interactions. J Mol Biol 248: 58-78, 1995.
34. Banks L, Matlashewski G, and Crawford L: Isolation of human p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 59: 529-534, 1986.
35. Legros Y, Lacabanne V, d' Agay MF, Larsen CJ, Pla M, and Soussi T: Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. Bull Cancer 80: 102-110, 1993.
36. Stephen CW, and Lane DP: Mutant conformation of p53. Precise epitope mapping using filamentous phage epitope library. J Mol Biol 225: 577-583, 1992.
37. Hartmann A, Blaszyk H, Saitoh S, Tsushima K, Tamura Y, Cunningham JM, Mc Govern RM, Schroeder JJ, Sommer SS, and Kovach JS: High frequency of p53 gene mutations in primary breast cancers in Japanese women, a low-incidence population. Br J Cancer 73: 896-901, 1996.
38. Home GM, Anderson JJ, Tiniakos DG, McIntosh GG, Thomas MD, Angus B, Henry, JA, Leonard, TWJ, and Home CHW: p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 73: 29-35, 1996.
39. Mousses S, McAuley L, Bell RS, Kandel R, and Andrulis IL: Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas. Mod Pathol 9: 1-6, 1996.
40. Momand J, Zambetti GP, Olson DC, George D, and Levine AJ: The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 69: 1237-1245, 1992.
41. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, and Vogelstein B: Oncoprotein mdm2 conceals the activation domain of tumour suppressorp53. Nature 362: 857-860, 1993.
42. Leach FS, Tokino T, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, and Vogelstein B: p53 mutations and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53: 2231-2234, 1993.
43. Perry ME, and Levine AJ: p53 and mdm-2: interactions between tumor suppressor gene and oncogene products. Mt Sinai J Med 61: 291-299, 1994.
44. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, and Pavletich NP: Structure of the MDM2 oncoproteine bound to the p53 tumor suppressor transactivation domain. Science 274: 948-53, 1996.
45. Stürzbecher HW, Addison C, and Jenkins JR: Characterization of mutant p53-hsp72/73 protein-protein complexes by transient expression in monkey COS cells. Mol Cell Biol 8: 3740-3747, 1988.
46. Ohuc M, Tomita N, Monden T, Fujita M, Fukunaga M, and Takami K: A frequent alteration of p53 gene in carcinoma in adenoma of colon. Cancer Res 54: 4798-4804, 1994.
47. Thorlacius S, Thorgilsson B, Björnsson J, Tryggvadottir L, Börresen AL, Ögmunddottir HM, and Eyfjörd JE: TP 53 mutations and abnormal p53 protein staining in breast carcinoma related to prognosis. Eur J Cancer 31: 1856-1861, 1995.
48. Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, and Sommer SS: Mutation detection by highly sensitive methods indicates that p53 mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 93: 1093-1096, 1996.